Ever-ambitious value-added medicines developer Hyloris Pharmaceuticals SA set out a busy year for itself as it announced its financial results for 2022, planning to conduct several clinical trials over the course of 2023 and launch its flagship intravenous analgesic Maxigesic IV (paracetamol/ibuprofen) 1,000mg/300mg in the US.
The firm successfully raised €15m ($15.9m) during what CEO Stijn Van Rompay described as an “exceptionally difficult year for both the financial markets and the healthcare sector”, as well as announcing HY-083, a candidate targeting idiopathic rhinitis